Alphamab Oncology Management
Management Kriterienprüfungen 2/4
Alphamab Oncology's CEO is Ting Xu, appointed in Nov 2008, has a tenure of 6.67 years. total yearly compensation is CN¥6.88M, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 33.06% of the company’s shares, worth HK$1.23B. The average tenure of the management team and the board of directors is 5.8 years and 5 years respectively.
Wichtige Informationen
Ting Xu
Geschäftsführender
CN¥6.9m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 95.2% |
Amtszeit als Geschäftsführer | 16yrs |
Eigentum des Geschäftsführers | 33.1% |
Durchschnittliche Amtszeit des Managements | 5.8yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 5yrs |
Jüngste Management Updates
Recent updates
Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -CN¥216m |
Mar 31 2024 | n/a | n/a | -CN¥213m |
Dec 31 2023 | CN¥7m | CN¥7m | -CN¥211m |
Sep 30 2023 | n/a | n/a | -CN¥214m |
Jun 30 2023 | n/a | n/a | -CN¥218m |
Mar 31 2023 | n/a | n/a | -CN¥272m |
Dec 31 2022 | CN¥7m | CN¥6m | -CN¥326m |
Sep 30 2022 | n/a | n/a | -CN¥309m |
Jun 30 2022 | n/a | n/a | -CN¥292m |
Mar 31 2022 | n/a | n/a | -CN¥352m |
Dec 31 2021 | CN¥7m | CN¥5m | -CN¥412m |
Sep 30 2021 | n/a | n/a | -CN¥502m |
Jun 30 2021 | n/a | n/a | -CN¥592m |
Mar 31 2021 | n/a | n/a | -CN¥510m |
Dec 31 2020 | CN¥5m | CN¥4m | -CN¥428m |
Sep 30 2020 | n/a | n/a | -CN¥652m |
Jun 30 2020 | n/a | n/a | -CN¥877m |
Mar 31 2020 | n/a | n/a | -CN¥851m |
Dec 31 2019 | CN¥5m | CN¥3m | -CN¥833m |
Vergütung im Vergleich zum Markt: Ting's total compensation ($USD969.67K) is above average for companies of similar size in the Hong Kong market ($USD399.57K).
Entschädigung vs. Einkommen: Ting's compensation has increased whilst the company is unprofitable.
Geschäftsführer
Ting Xu (51 yo)
16yrs
Amtszeit
CN¥6,877,000
Vergütung
Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Founder | 16yrs | CN¥6.88m | 33.06% HK$ 1.2b | |
VP of Corporate Operations & Executive Director | 6.1yrs | CN¥2.97m | keine Daten | |
Vice President of Government Affairs & Public Relations | 5.8yrs | keine Daten | keine Daten | |
Senior Vice President of Business Development | 6.5yrs | keine Daten | keine Daten | |
Chief Commercial Officer | 3yrs | keine Daten | keine Daten | |
Joint Company Secretary | 4.3yrs | keine Daten | keine Daten | |
Joint Company Secretary | less than a year | keine Daten | keine Daten |
5.8yrs
Durchschnittliche Betriebszugehörigkeit
51.5yo
Durchschnittliches Alter
Erfahrenes Management: 9966's management team is seasoned and experienced (5.8 years average tenure).
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Founder | 6.7yrs | CN¥6.88m | 33.06% HK$ 1.2b | |
VP of Corporate Operations & Executive Director | 6.1yrs | CN¥2.97m | keine Daten | |
Independent Non-Executive Director | 5yrs | CN¥396.00k | keine Daten | |
Non-Executive Director | less than a year | keine Daten | 0.11% HK$ 4.0m | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Non-Executive Director | 5yrs | CN¥396.00k | keine Daten | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Chairman of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Non-Executive Director | 3.3yrs | CN¥378.00k | keine Daten |
5.0yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrener Vorstand: 9966's board of directors are considered experienced (5 years average tenure).